|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CTGF, intestinal stellate cells and carcinoid fi brogenesis显示文摘AIM: To investigate the role of small intestinal carcinoid tumor-derived fibrotic mediators, TGFβ1 and CTGF, in the mediation of fi brosis via activation of an 'intestinal' stellate cell. METHODS: GI carcinoid tumors were collected for Q RT-PCR analysis of CTGF and TGFβ1. Markers of stellate cell desmoplasia were identified in peritoneal fibrosis by immunohistochemistry and stellate cells cultured from fresh resected fibrotic tissue. CTGF and TGFβ1 were evaluated using quantitative tissue array profi ling (AQUA analysis) in a GI carcinoid tissue microarray (TMA) with immunostaining and correlated with clinical and histologically documented fi brosis. Serum CTGF was analyzed using a sandwich ELISA assay. RESULTS: Message levels of both CTGF and TGFβ1 in SI carcinoid tumors were signifi cantly increased (> 2-fold, P < 0.05) versus normal mucosa and gastric (non-f ibrotic) carcinoids. Activated stellate cells and markers of stellate cell-mediated fi brosis (vimentin, desmin) were identifi ed in histological fibrosis. An intestinal stellate cell was immunocytochemically and biochemically characterized and its TGFβ1 (10-7M) initiated CTGF transcription response (> 3-fold, P < 0.05) demonstrated. In SI carcinoid tumor patients with documented fi brosis, TMA analysis demonstrated higher CTGF immunostaining (AQUA Score: 92 ± 8; P <0.05), as well as elevated TGFβ1 (90.6 ± 4.4, P < 0.05). Plasma CTGF (normal 12.5 ± 2.6 ng/mL) was increased in SI carcinoid tumor patients (31 ± 10 ng/mL, P < 0.05) compared to non-fi brotic GI carcinoids (< 15 ng/mL).CONCLUSION: SI carcinoid tumor fibrosis is a CTGF/ TGFβ1-mediated stellate cell-driven fibrotic response. The delineation of the biology of fibrosis will facilitate diagnosis and enable development of agents to obviate its local and systemic complications. | M Kidd IM Modlin MD Shapiro RL Camp SM Mane W Usinger JR Murren | 2007 | World Journal of Gastroenterology2007，13，39： | 5 |
| 2 | Advances in chemotherapy for small cell lung cancer:single-agent activity of newer agents 显示文摘 | Murren JR | 2001 | Cancer J2001，7，3： | 1 |
| 3 | Progress in the therapy of small cell lung cancer显示文摘 | Simon M Argiris A Murren JR | 2004 | Crit Rev Oncol Hematol2004，49，2： | 1 |
| 4 | Critical analysis of neoadjuvant therapy for stage Ⅲ a non-small cell lung cancer显示文摘 | Buzaid AC Hait WN | 1991 | Am Rev Resp Dis1991，143，4： | 1 |
| 5 | Docelaxel and irinolecan, alone and in combination, in the treatment of non-small cell lung cancer 显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Sere in Oncol1999，26，6： | 1 |
| 6 | Docetaxel and irinotecan, alone and in combinnatiom, in the treatment of non - small cell lung cancer 显示文摘 | Adjei AA Argiris A Murren Jr | 1999 | Semin Oncol1999，26，5： | 1 |
| 7 | Progress in the therapy of small Cell lung cancer显示文摘 | Simon M Argiris A Murren JR | 2004 | Crit Rev Oncol Hematol2004，49，2： | 1 |
| 8 | Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents 显示文摘 | Argiris A Murren JR | 2001 | Cancer J2001，7，3： | 1 |
| 9 | Staging and clinical prognostic factors for small-cell lung cancer 显示文摘 | Argifis A Murren JR | 2001 | Cancer J2001，7，5： | 1 |
| 10 | Critical analysis of neoadjuvant therapy for stage IIIa non small cell lung cancer显示文摘 | Murren JR Buzaid AC Hait WN | 1991 | AM Rev Resp Dis1991，143，4： | 1 |
| 11 | Progress in the therapy of small cell lung cancer显示文摘 | Simon M Argiris A Murren JR | 2004 | Crit Rev Oncol Hematol2004，49，2： | 1 |
| 12 | Docetaxel and irinotecan,alone and in combination,in the treatment of nonsmall cell lung cancer显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Semin Oncol1999，26，16： | 1 |
| 13 | Dcetaxel and irinotecan,alone and in combination,in the treatment of non-small cell lung cancer显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Semin Oncol1999，26，516： | 1 |
| 14 | Docetaxel and irinotecan,alone and in combination,in the treatment of non-small cell lung cancer显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Semin Oncol1999，，： | 1 |
| 15 | Doeetaxel and irinotecan,alone and in combination,in the treatment of non-small cell lung cancer显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Semin Oncol1999，26，16： | 1 |
| 16 | Progress in the therapy of small cell lung cancer 显示文摘 | Simon M Argirls A Murren JR | 2004 | Critical reviews in oncology/hematology2004，49，2： | 1 |
| 17 | Erlotinib OSI/Roche/Genentech 显示文摘 | KIM TE MURREN JR | 2002 | Curr Opin Investig Drugs2002，3，9： | 1 |
| 18 | Docetaxel and irinotecan,alone and in combination, in the treatment of non-small cell lung cancer显示文摘 | Adjei AA Argiris A Murren JR | 1999 | Semin Oncol1999，26，516： | 1 |
| 19 | Lapatinib ditosylate GlaxoSmithKline显示文摘 | Kim TE Murren JR | 2003 | IDrugs2003，6，9： | 1 |
| 20 | Staging and clinical prognostic factors for small -cell lung cancer显示文摘 | Argiris A Murren JR | 2001 | Cancer J2001，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员